BeiGene Overview
BeiGene (BGNE) has a ROE of 12.67%, below the Healthcare sector average of 22.76%.
Get informed when a big investor buys or sells
+ Follow12.67%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, BGNE shows a ROE of 12.67%. That is below the Healthcare sector average of 22.76%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 22.76%. BeiGene is at 12.67%, which is lower that average. That is roughly 44.3% below the sector mean. Use the comparison chart on this page to see how BGNE stacks up against individual peers as well.
Check the historical chart to see whether BGNE's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare BeiGene with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has BeiGene's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 12.67%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 22.76%, while BGNE is at 12.67%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
